

Special Issue

Drug Discovery, Drug Targets, Biomarkers and Biological Models for Diseases Caused by Parasitic Helminths

Message from the Guest Editor

Parasitic nematodes, trematodes, cestodes, and flatworms together infect more than a billion humans worldwide every year, but research into their biology and treatment remains neglected. The diagnosis of infections and their treatment are the two key components in reducing the disease burden caused by these parasites. The recent advances in the genomics, transcriptomics, proteomics, and glycomics of parasites as well as their hosts and vectors has accelerated the research in these areas. The successful use of antibiotics against endosymbionts such as *Wolbachia* in some filarial parasites has also emerged as another promising avenue in the search for new drug targets. In addition, the effects of the host and parasite microbiota on the disease dynamics continue to be explored. This Special Issue focuses on the latest advances in the diagnosis of infections, the development of new drugs and drug candidates for use in humans and animals, and basic research on helminthic parasites using various lab models. Authors are invited to submit original research articles or comprehensive reviews on any of these areas.

Guest Editor

Dr. Amit Sinha

New England Biolabs Inc., Ipswich, MA, USA

Deadline for manuscript submissions

closed (15 April 2022)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/84567

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).